AzurRx BioPharma Inc (AZRX) Given $8.25 Average Price Target by Brokerages

AzurRx BioPharma Inc (NASDAQ:AZRX) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus target price of $8.25 for the company and are anticipating that the company will post ($0.23) EPS for the current quarter, according to Zacks. Zacks has also given AzurRx BioPharma an industry rank of 179 out of 265 based on the ratings given to its competitors.

Separately, HC Wainwright set a $8.00 price objective on shares of AzurRx BioPharma and gave the stock a “buy” rating in a report on Friday.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AZRX. Susquehanna International Group LLP bought a new position in AzurRx BioPharma in the 3rd quarter worth approximately $131,000. Ardsley Advisory Partners bought a new position in AzurRx BioPharma in the 2nd quarter valued at $141,000. IHT Wealth Management LLC boosted its holdings in AzurRx BioPharma by 15.3% in the 2nd quarter. IHT Wealth Management LLC now owns 3,498 shares of the company’s stock valued at $486,000 after purchasing an additional 464 shares during the period. Finally, Parsons Capital Management Inc. RI boosted its holdings in AzurRx BioPharma by 37.2% in the 3rd quarter. Parsons Capital Management Inc. RI now owns 254,263 shares of the company’s stock valued at $1,015,000 after purchasing an additional 68,920 shares during the period. 8.18% of the stock is owned by institutional investors.

AzurRx BioPharma (NASDAQ:AZRX) traded down $0.07 on Friday, reaching $3.34. 28,543 shares of the company traded hands, compared to its average volume of 64,151. AzurRx BioPharma has a 52 week low of $2.40 and a 52 week high of $5.25.

AzurRx BioPharma (NASDAQ:AZRX) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.13). analysts predict that AzurRx BioPharma will post -1.05 earnings per share for the current year.

WARNING: “AzurRx BioPharma Inc (AZRX) Given $8.25 Average Price Target by Brokerages” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/20/azurrx-biopharma-inc-azrx-given-8-25-average-price-target-by-brokerages.html.

About AzurRx BioPharma

AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply